On waking up and switching on my radio early on the morning of Friday, 24 June 2016, I was devastated to hear that the citizens of the UK had voted to leave the European Union (EU).
I would not hesitate to describe myself as a European, who happens also to be British and English, having been born and raised in Norwich in the county of Norfolk. I have lived and travelled extensively in Europe, and I have long been convinced, encouraged by my own experience, that the UK should be a fully committed and active member of the EU.
There will now be a long period of uncertaintylasting at least years, and possibly even decadesas nobody knows what needs to be negotiated and decided, how the negotiations should be conducted and how the decisions should be made, or what the eventual effects are likely to be, not only on the UK's own interests and fate, but also on those of the remaining EU Member States and the world as a whole.
The "world as a whole" involves many different considerations, including, in the context of this Editorial, human and animal health and welfare, and the biomedical sciences, as well as the various industries, institutions and regulations which can affect them.
It happened that, less than a month after the referendum outcome was announced, the Home Office report, Annual Statistics of Scientific Proced ures Great Britain 2015 (2015 Statistics), was presented to Parliament and ordered by the House of Commons to be printed. 1 This brought into sharp focus the question of whether the UK will continue to apply the Animals (Scientific Proced ures) Act 1986 (ASPA), as amended in 2013 2 in compliance with the requirements of the European Directive, Directive 10/63/EU, 3 or whether the decision will be taken to revert to the pre-existing version of the ASPA.
The Directive spells out a common format to be used by all the Member States when submitting information to the European Commission (EC) on the use of animals for scientific purposes. This made necessary a number of changes to the administration of the ASPA with effect from 2014, including the following, as usefully listed in the Introductory Note in the 2015 Statistics:
-In order to allow for the collection of data on actual severity of procedures, the reported data are for procedures completed, as opposed to procedures started, as had been reported prior to 2014.
-Details of the actual severity are recorded for all procedures. This is an assessment of the severity that animals experienced as a result of the entire procedure applied and reflects the peak severity of that procedure.
-The species information collected has been revised: information on all cephalopods, as opposed to only one species (Octopus vulgaris), is now collected; data on greyhounds are no longer collected separately; however, since 2015, species information is collected to distinguish beagles from other dogs and the common quail from other birds.
-Information on free-feeding larval forms (e.g. tadpoles) is now collected, but unborn or unhatched embryos are not counted.
-Precise information on the number of individual animals re-used is not collected; however, it is still possible to ascertain the number of procedures which involved the re-use of animals. -Information on target body system is no longer collected for all procedures, but similar data are collected for procedures undertaken for basic and translational research purposes.
-Specific information is collected on regulatory (as opposed to non-regulatory) use; some of this information was previously reported as applied studies.
On the whole, these are very sensible and valuable provisions, and it is to be hoped that common sense will prevail, so that statistics which are in line with those required by the EC from the remaining Member States will continue to be collected and published. This will permit progress made in the UK to be monitored against the wider background of the EU. There are, of course, many other aspects of the protection of animals used for scientific purposes, which could be altered as the UK distances itself from the legislation of the EU. The analysis of what could happen, and the need for vigilance as events unfold, will be kept under review in ATLA. In addition, there will as usual be a detailed review of the latest UK statistics. Nevertheless, the opportunity to make a few comments on the 2015 Statistics is irresistible, especially where non-human primates (NHPs) were involved.
A total of 4.14 million procedures were completed in the UK in 2015, an increase of 1% over the 2013 number (as there were data quality issues with the 2014 statistics). This included a 12% increase (to 3,612) in the number of procedures involving NHPs.
As expected, most of the procedures involving NHPs (3,140 of 3,600) were conducted on cynomolgus macaques used for regulatory purposes; 224 NHP procedures were classified as "basic research" and 245 as "translational/applied research". Since 1987, when the original ASPA came into effect, and according to a suggestion made to the then Home Secretary by FRAME and CRAE, procedures involving NHPs have been subdivided into those on New World monkeys (all marmosets in 2015) and Old World monkeys (all macaques in 2015). Almost all the marmosets used for the first time in 2015 (114 of 115) were born in the UK, whereas 90% of the macaques (2013 of 2119) had been imported from Africa or Asia. This raises questions about the stress involved in the international transport of the macaques.
One of the key aspects of the 2015 Statistics is the severity of the procedures to which the animals were exposed, summarised in Table 3 .1. It was somewhat disappointing that the NHPs involved are referred to as a single group, but, given the distribution of the total numbers and their uses, it is clear that the severity values overwhelmingly refer to macaques. The distribution was as follows: subthreshold (no procedures), non-recovery (29 procedures), mild (2,624 procedures), moderate (931 procedures), and severe (28 procedures), of a total of 3,612 procedures.
The 2015 Statistics show that 4,643 procedures involved dogs, of which 330 were for basic research, 802 for translational/applied research, and 3,511 for regulatory purposes. The severity distribution was: sub-threshold (14 procedures), non-recovery (49 procedures), mild (3,097 procedures), moderate (1,480 procedures), and severe (3 procedures). Most of the dogs (3,241 of 3,405) were beagles, of which 1,976 were born in the UK and 253 elsewhere in the EU. It is a matter of concern that 1,012 of them were born in the "rest of the world", which again raises questions of stress during transport.
I have focused on NHPs and dogs in these brief comments, as I have long been concerned about the use of these animals for regulatory purposes related to pharmaceuticals and in stressful procedures. In addition, with my colleagues, Michelle Thew and Jarrod Bailey, I have recently published convincing evidence that no one species can be used to predict drug toxicity in any other species. 4 This enables us to question the scientific justification for the use of 3,140 macaques and 3,511 dogs in UK laboratories in 2015. We hope that our concerns will be taken seriously, not only in the UK, but also by the European Medicines Agency. 
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